Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

China · Delayed Price · Currency is CNY

38.24

+0.85 (2.27%)

Jul 1, 2026, 11:30 AM CST

4.31% (1Y)

Market Cap	11.90B -2.3%
Revenue (ttm)	2.99B +6.3%
Net Income	967.36M -4.0%
EPS	3.00 -4.1%
Shares Out	318.32M
PE Ratio	12.46
Forward PE	n/a
Dividend	1.76 (4.62%)
Ex-Dividend Date	May 22, 2026

Volume	3,680,194
Open	37.28
Previous Close	37.39
Day's Range	36.21 - 38.25
52-Week Range	34.80 - 57.98
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-releas... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1999

Employees 671

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600211

Full Company Profile

Financial Performance

In 2025, SHA:600211's revenue was 2.98 billion, an increase of 6.23% compared to the previous year's 2.81 billion. Earnings were 937.93 million, a decrease of -10.78%.

Financial Statements